To Successfully Manage a Pharma Communications Crisis, Your Team Needs These Six Roles Filled

Jerry Doyle  |  April 2, 2026

Healthcare • Strategy • Tips

To Successfully Manage a Pharma Communications Crisis, Your Team Needs These Six Roles Filled

By Jerry Doyle

In the pharmaceutical industry, a communications crisis can materialize faster than a quarterback sneak on fourth and one —from a safety signal to an FDA action to a social media surge. The clock continues to run, with a devastating potential impact on stock price, regulatory scrutiny, and brand reputation.

What do the best pharma companies have in common with the best football teams? It’s usually not a matter of information or resources: it’s whether they have figured out the key roles and assembled their key players well in advance of the championship game. Those that stumble, on the other hand, are the ones scrambling to fill roles with a last-minute call-up from the bench.

In pharma, a crisis can escalate in hours. The difference between control and chaos isn’t just speed—it’s preparation. And that starts with having the right team.

What is a pharma crisis communications team?

A pharma crisis communications team is a cross-functional group responsible for managing messaging, compliance, and stakeholder communication during high-risk events such as safety issues, recalls, or regulatory actions.

1. Executive Leadership (Your Quarterback)

The one calling the plays under pressure.

Your CEO or President sets the tone and may need to be the face of your company when a crisis demands executive ownership. It’s essential that your C-suite sponsor is briefed and ready to speak with a credible, empathetic voice—not improvise plays on the field.

2. Legal and Regulatory Affairs (Your Offensive Line)

Nobody notices them until there’s a sack.

In a crisis, your legal counsel will flag liability exposure, while your regulatory affairs team will ensure all communications remain compliant with FDA guidelines, including rules around off-label claims and promotional language. These players should be integrated from the first hour, not brought in at the end to slow everything down.

3. Medical and Scientific Affairs (Your Tight End)

Versatile, precise, and clutch when it matters most.

When a drug safety issue is at the center of the crisis, you need credible scientific voices who can translate complex clinical data into clear, accurate language. Medical Affairs professionals bridge the gap between the data and the message, ensuring that what you communicate is both scientifically defensible and publicly understandable.

4. Communications and Public Relations (Your Coach)

The one with the game plan and the headset.

Your internal communications team (or your agency partner) shapes the narrative, drafts statements, manages media inquiries, monitors social channels, and coordinates all external messaging. A PR leader with pharma experience is invaluable, bringing the discipline to stay on message while adapting to rapidly changing information.

5. Government and Public Affairs (Your Center)

The anchor everyone depends on but rarely credits.

When a crisis involves FDA scrutiny, Congressional attention, or state-level regulatory response, you need a government affairs leader who understands the political landscape and maintains relationships with key stakeholders. Proactive, transparent engagement with regulators during a crisis can make a meaningful difference in outcomes.

6. Patient and Customer Advocacy Liaison (Your Running Back)

A reliable constant so the drive keeps moving.

Patients are your most important— and often most overlooked—audience. A designated patient liaison ensures that communications remain compassionate, accessible, and centered on safety.

Readiness Is a Year-Round Discipline

Signing the right players for your team is an essential first step. Preparing for the clutch game requires practice. These individuals need to work together with simulations and tabletop exercises, align on protocols, and establish clear decision-making hierarchies before a crisis hits. Messaging frameworks, pre-approved statement templates, and media spokesperson training should all be in place well in advance.

Unless you’re sure your crisis team is ready to make a goal-line stand, consider outside training expertise and guidance. Unlike many generalists, Yes& CommCore has decades of specific experience in addressing issues resulting from deviations, supply chain disruptions, and quality issues in pharmaceutical manufacturing.

Case example: Managing a high-pressure patient access crisis

A global biotechnology company faced mounting pressure from patient advocacy groups over limited drug access due to high costs. Protests—including a planned march—threatened to disrupt operations.

Our approach:

  • Defined clear spokesperson and on-site response roles
  • Aligned internal and external stakeholders
  • Prepared for high inquiry volume
  • Deployed QR codes to route stakeholders to real-time information

Outcome:
This approach ensured message consistency, reduced operational disruption, and strengthened trust during a highly visible and sensitive situation.

Pharma Crisis Communications FAQs

What is a pharma crisis communication plan?

A pharma crisis communication plan outlines how a company will respond to safety issues, regulatory actions, or public scrutiny with clear, compliant messaging.

Who should be on a crisis response team in healthcare?

A cross-functional team including leadership, legal, medical, communications, government affairs, and patient advocacy.

Why is medical affairs important in a crisis?

They ensure all communications are scientifically accurate and defensible.

How fast should a pharma company respond to a crisis?

Ideally within hours, with a coordinated response in place within 24 hours.

What makes a crisis response effective?

Preparation, clear roles, consistent messaging, and alignment across stakeholders.

Not sure your team could respond within 24 hours?

Request a 30-minute Pharma Crisis Readiness Assessment—and we’ll help you identify gaps before they become liabilities.

Subscribe to the Ampersand Newsletter for insights from Yes&